LifeMD Inc

LifeMD Inc (LFMD) Stock Analysis

$2.290

-0.150 (-6.53%)At close

Loading chart…
High
2.490
Open
2.460
VWAP
2.33
Volume
597.21K
Mkt Cap
279.29M
Low
2.205
Amount
1.39M
EV/EBITDA, TTM
-3.54

LifeMD, Inc. is a patient-centric, direct-to-patient healthcare company. The Company is engaged in providing patients access to virtual medical care and pharmacy services. Its telehealth platform helps patients access licensed providers for diagnoses, virtual care, and prescription medications, often delivered on a recurring basis and sells over the counter (OTC) products. Its products are available on a subscription or membership basis, where a patient can subscribe to receive regular shipments of prescribed medications or products. The Company's men's brand, RexMD, offers access to virtual medical treatment for a variety of men's health needs, including erectile dysfunction, premature ejaculation and hair loss. Its vertically integrated care model combines technology, affiliated clinical services, pharmacy infrastructure, and artificial intelligence (AI)-enabled operational systems to deliver longitudinal care.

lifemd.com

AI analysis of LifeMD Inc (LFMD)

Buy

LifeMD Inc appears to be a good buy right now due to its current price of $2.31, which is significantly below its 52-week high of $5.73, indicating potential for upside. The stock has a forward P/E ratio of 12.85, suggesting it may be undervalued compared to future earnings. Additionally, the RSI is at 55.54, indicating the stock is neither overbought nor oversold, which is a favorable technical indicator. However, the main risk is the company's net income, which has been negative, with a reported loss of $9.64 million in Q1 2026, highlighting ongoing financial challenges.

Valuation Metrics

The current forward P/E ratio for LifeMD Inc (LFMD) is 12.85, compared to its 5-year average forward P/E of -15.58.

Forward P/E

Fair
5Y Average P/E
-15.58
Current P/E
12.85
Overvalued
43.95
Undervalued
-75.10

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
5.86
Current EV/EBITDA
-3.54
Overvalued
18.37
Undervalued
-6.64

Forward P/S

Undervalued
5Y Average P/S
0.93
Current P/S
0.48
Overvalued
1.37
Undervalued
0.49

Alphio AI Price Scenarios for LFMD

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%LFMD

$14.58

Scenario price

B

Base

Base · 50%LFMD

$13.42

Scenario price

B

Bear

Bear · 25%LFMD

$9.37

Scenario price

Events Timeline

2026-11-05 (ET)

10:00:00

LifeMD Partners with Eli Lilly for Direct GLP-1 Drug Dispensing

2026-09-17 (ET)

12:00:00

H.C. Wainwright Gives LifeMD Buy Rating, Price Target $9

2026-08-05 (ET)

18:30:00

LifeMD Sees Q3 Adjusted EBITDA Loss of $1M to Gain of $2M

18:30:00

LifeMD Cuts FY26 Revenue Outlook to $6B Loss

News

LFMD FAQ — answered by Alphio AI

LifeMD, Inc. is a patient-centric, direct-to-patient healthcare company. The Company is engaged in providing patients access to virtual medical care and pharmacy services. Its telehealth platform helps patients access licensed providers for diagnoses, virtual care, and prescription medications, often delivered on a recurring basis and sells over the counter (OTC) products. Its products are available on a subscription or membership basis, where a patient can subscribe to receive regular shipments of prescribed medications or products. The Company's men's brand, RexMD, offers access to virtual medical treatment for a variety of men's health needs, including erectile dysfunction, premature ejaculation and hair loss. Its vertically integrated care model combines technology, affiliated clinical services, pharmacy infrastructure, and artificial intelligence (AI)-enabled operational systems to deliver longitudinal care. It operates in the Healthcare sector (SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE industry).

LifeMD Inc appears to be a good buy right now due to its current price of $2.31, which is significantly below its 52-week high of $5.73, indicating potential for upside. The stock has a forward P/E ratio of 12.85, suggesting it may be undervalued compared to future earnings. Additionally, the RSI is at 55.54, indicating the stock is neither overbought nor oversold, which is a favorable technical indicator. However, the main risk is the company's net income, which has been negative, with a reported loss of $9.64 million in Q1 2026, highlighting ongoing financial challenges.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading